2-Arachidonoylglycerol

• The Role of Cannabinoids in Allergic Diseases: Collegium Internationale Allergologicum (CIA) Update 2020 (16 Sep 2024)
  
• Omega-6 and omega-3 fatty acids: Endocannabinoids, genetics and obesity (16 Sep 2024)
  
• Cannabis hyperemesis syndrome: an update on the pathophysiology and management (16 Sep 2024)
  
• Cannabinoids and triple-negative breast cancer treatment (03 Sep 2024)
  
• The Relationship between Muscarinic and Cannabinoid Receptors in Neuronal Excitability and Epilepsy: A Review (02 Sep 2024)
  
• The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer’s Disease (02 Sep 2024)
  
• Role of the CB2 Cannabinoid Receptor in the Regulation of Food Intake: A Systematic Review (02 Sep 2024)
  
• Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[d]imidazole-Based Cannabinoid Type 2 (CB2) Receptor Agonists (02 Sep 2024)
  
• Molecular Advances on Cannabinoid and Endocannabinoid Research (02 Sep 2024)
  
• Hemp Seed Oil Inhibits the Adipogenicity of the Differentiation-Induced Human Mesenchymal Stem Cells through Suppressing the Cannabinoid Type 1 (CB1) (02 Sep 2024)
  
• Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1 (02 Sep 2024)
  
• Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality (02 Sep 2024)
  
• A collection of cannabinoid-related negative findings from autaptic hippocampal neurons (30 Aug 2024)
  
• Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling (29 Aug 2024)
  
• Cannabinoid Signaling in Kidney Disease (29 Aug 2024)
  
• The endocannabinoid systemʼs involvement in motor development relies on cannabinoid receptors, TRP channels, and Sonic Hedgehog signaling (28 Aug 2024)
  
• Microglial Cannabinoid CB2 Receptors in Pain Modulation (28 Aug 2024)
  
• Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders (28 Aug 2024)
  
• Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases (28 Aug 2024)
  
• Voltage dependence of the cannabinoid CB1 receptor (27 Aug 2024)
  
• Therapeutic Use of Cannabis in Inflammatory Bowel Disease (27 Aug 2024)
  
• The Enteric Glia and Its Modulation by the Endocannabinoid System, a New Target for Cannabinoid-Based Nutraceuticals? (27 Aug 2024)
  
• Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer’s disease (27 Aug 2024)
  
• Molecular Insights into Epigenetics and Cannabinoid Receptors (27 Aug 2024)
  
• A Critical Evaluation of Terpenoid Signaling at Cannabinoid CB1 Receptors in a Neuronal Model (27 Aug 2024)
  
• Impact of Cannabinoid Compounds on Skin Cancer (21 Aug 2024)
  
• Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry (20 Aug 2024)
  
• Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting (20 Aug 2024)
  
• Metabolic Consequences of Gestational Cannabinoid Exposure (20 Aug 2024)
  
• Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox (20 Aug 2024)
  
• Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease (20 Aug 2024)
  
• Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention (20 Aug 2024)
  
• Towards A Molecular Understanding of The Cannabinoid Related Orphan Receptor GPR18: A Focus on Its Constitutive Activity (19 Aug 2024)
  
• Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease (19 Aug 2024)
  
• Interaction between cannabinoid and nucleotide systems as a new mechanism of signaling in retinal cell death (19 Aug 2024)
  
• Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology (19 Aug 2024)
  
• Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges (18 Aug 2024)
  
• Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System (18 Aug 2024)
  
• Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation (12 Aug 2024)
  
• A helping HAND: therapeutic potential of MAGL inhibition against HIV-1-associated neuroinflammation (24 May 2024)
  
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy (13 May 2024)
  
• Role of the Endocannabinoid System in Metabolic Control Processes and in the Pathogenesis of Metabolic Syndrome: An Update (27 Feb 2023)
  
• Endocannabinoid System: Chemical Characteristics and Biological Activity (27 Feb 2023)
  
• Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review (27 Feb 2023)
  
• The Endocannabinoid System as a Pharmacological Target for New Cancer Therapies (05 Sep 2022)
  
• Quality of Life and a Surveillant Endocannabinoid System (05 Sep 2022)
  
• Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors? (05 Sep 2022)
  
• Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation (05 Sep 2022)
  
• The Role of Cannabinoids in Bone Metabolism: A New Perspective for Bone Disorders (01 Sep 2022)
  
• Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses (01 Sep 2022)
  
• Endocannabinoid Metabolism and Traumatic Brain Injury (01 Sep 2022)
  
• Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression (27 Aug 2022)
  
• New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence (27 Aug 2022)
  
• Enhancing Endocannabinoid Control of Stress with Cannabidiol (27 Aug 2022)
  
• Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition (13 Aug 2022)
  
• Considerations for Cannabinoids in Perioperative Care by Anesthesiologists (13 Aug 2022)
  
• Components of the Endocannabinoid System and Effects of Cannabinoids Against Bone Diseases: A Mini-Review (13 Aug 2022)
  
• The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study (07 Aug 2022)
  
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation (05 Aug 2022)
  
• Targeting the Endocannabinoidome in Pancreatic Cancer (05 Aug 2022)
  
• Endocannabinoid-Mediated Control of Neural Circuit Excitability and Epileptic Seizures (05 Aug 2022)
  
• Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option? (05 Aug 2022)
  
• The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies (31 Jul 2022)
  
• Endocannabinoid System and Migraine Pain: An Update (25 Jul 2022)
  
• Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review (21 Jul 2022)
  
• Endocannabinoid Discovery Timeline (21 Jul 2022)
  
• Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease (20 Jul 2022)